Development of a Mycobacterium bovis intranasal challenge model in mice

Tuberculosis

Volumn 88, Issue 5, 2008, Pages 437-443

  Logan, Karen E ^a   Gavier Widen, Dolores ^b   Hewinson, R Glyn ^a   Hogarth, Philip J ^a  

^a VETERINARY LABORATORIES AGENCY   (United Kingdom)

^b NATIONAL VETERINARY INSTITUTE   (Sweden)

Author keywords

Intranasal; Model; Mouse; Mycobacterium bovis; Vaccine

Indexed keywords

BCG VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BCG VACCINATION; CATTLE DISEASE; CONTROLLED STUDY; DISEASE MODEL; FEMALE; KINETICS; MOUSE; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ADMINISTRATION, INTRANASAL; ANIMALS; BCG VACCINE; CATTLE; DISEASE MODELS, ANIMAL; FEMALE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, BOVINE;

EID: 49349104287     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2008.05.005     Document Type: Article

References (17)

1. Kochi A. The global tuberculosis situation and the new control strategy of the World Health Organization. Tubercle 72 (1991) 1-6
2. EEC directive 90/219 amending directive 64/432 annex B; 1980.
3. Orme I.M., McMurray D.N., and Belisle J.T. Tuberculosis vaccine development: recent progress. Trends Microbiol 9 (2001) 115-118
4. Krebs J.R. Bovine tuberculosis in cattle and badgers. Ministry of Agriculture (1997), Fisheries and Food, London
5. ISG Scoping sub-committee. Development of vaccines for bovine tuberculosis: Report of the ISG vaccine scoping sub-committee (2003), Defra, London
6. Bloom B.R., and Fine P.E. The BCG experience: implications for future vaccines against tuberculosis. In: Bloom B.R. (Ed). Tuberculosis: pathogenesis, protection and control (1994), ASM Press, Washington, DC 531-557
7. Hogarth P.J., Hewinson R.G., and Vordermeier H.M. Development of vaccines against bovine tuberculosis. J Pharm Pharmacol 58 (2006) 749-757
8. Francis J. Bovine tuberculosis (1947), Staples Press
9. Hewinson R.G., Vordermeier H.M., and Buddle B.M. Use of the bovine model of tuberculosis for the development of improved vaccines and diagnostics. Tuberculosis (Edinb) 83 (2003) 119-130
10. Orme I.M. The use of animal models to guide rational vaccine design. Microbes Infect 7 (2005) 905-910
11. Cardona P.J., Cooper A., Luquin M., Ariza A., Filipo F., Orme I.M., et al. The intravenous model of murine tuberculosis is less pathogenic than the aerogenic model owing to a more rapid induction of systemic immunity. Scand J Immunol 49 (1999) 362-366
12. North R.J. Mycobacterium tuberculosis is strikingly more virulent for mice when given via the respiratory than via the intravenous route. J Infect Dis 172 (1995) 1550-1553
13. North R.J., LaCourse R., and Ryan L. Vaccinated mice remain more susceptible to Mycobacterium tuberculosis infection initiated via the respiratory route than via the intravenous route. Infect Immun 67 (1999) 2010-2012
14. Gallagher J., and Horwill D.M. A selective oleic acid albumin agar medium for the cultivation of Mycobacterium bovis. J Hyg (Lond) 79 (1977) 155-160
15. Orme I.M. Mouse model of tuberculosis. In: Bloom B.R. (Ed). Tuberculosis: pathogenesis, protection and control (1994), ASM Press, Washington, DC
16. Eruslanov E.B., Majorov K.B., Orlova M.O., Mischenko V.V., Kondratieva T.K., Apt A.S., et al. Lung cell responses to M. tuberculosis in genetically susceptible and resistant mice following intratracheal challenge. Clin Exp Immunol 135 (2004) 19-28
17. Medina E., Ryan L., LaCourse R., and North R.J. Superior virulence of Mycobacterium bovis over Mycobacterium tuberculosis (Mtb) for Mtb-resistant and Mtb-susceptible mice is manifest as an ability to cause extrapulmonary disease. Tuberculosis (Edinb) 86 (2006) 20-27